Mode
Text Size
Log in / Sign up

Biofilm-driven chronic rhinosinusitis: review reframes recalcitrance as immune and ecological dysregulation

Biofilm-driven chronic rhinosinusitis: review reframes recalcitrance as immune and ecological dysreg…
Photo by Kelly Sikkema / Unsplash
Key Takeaway
Consider biofilm-driven immune dysregulation in recalcitrant CRS when FESS and antimicrobial monotherapy fail to control disease.

This is a narrative review synthesizing mechanistic and therapeutic evidence on biofilm-associated chronic rhinosinusitis (CRS). The authors frame treatment recalcitrance as a consequence of persistent microbial biofilms that function not only as physical barriers to antibiotics but as active immune modulators perpetuating mucosal dysbiosis.

Mechanistically, the review describes how biofilm-derived pathogen-associated molecular patterns (PAMPs) trigger release of epithelial alarmins — TSLP, IL-33, and IL-25 — fueling a maladaptive Type 2 inflammatory loop. The authors also examine bacterial survival strategies, including small colony variants (SCVs) and intracellular "Trojan Horse" reservoirs, which the authors state render conventional functional endoscopic sinus surgery (FESS) and antimicrobial monotherapies insufficient for complete eradication.

The review highlights a diagnostic disconnect in which standard cultures fail to detect biofilm burdens, limiting recognition of the underlying driver in routine practice. Building on this, the authors propose a therapeutic paradigm shift from a purely bactericidal approach toward ecological restoration, integrating matrix-degrading enzymes, bacteriophage cocktails, and Nasal Microbiota Transplantation (NMT) into a multi-dimensional framework aimed at restoring sinonasal homeostasis.

As a narrative synthesis, the piece does not report pooled effect estimates, comparative efficacy data, or adverse-event rates for the emerging strategies discussed, and safety and tolerability of phages, enzymatic debridement, or NMT were not quantified in the abstract. The proposed framework is conceptual rather than evidence-graded.

For clinicians managing recalcitrant CRS, the review supports considering biofilm biology and host immune response when conventional FESS and antibiotics fail, and anticipating emerging adjuncts that target matrix, microbial ecology, and Type 2 inflammation rather than bacterial killing alone.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
The management of chronic rhinosinusitis (CRS) is frequently complicated by treatment recalcitrance, a phenomenon primarily driven by the persistence of microbial biofilms. Beyond their traditional role as a physical barrier against antibiotics, recent evidence positions biofilms as sophisticated immune modulators that actively perpetuate mucosal dysbiosis. This review synthesizes the pathological continuum of biofilm-associated CRS, elucidating how biofilm derived pathogen associated molecular patterns (PAMPs) trigger the release of epithelial alarmins (TSLP, IL-33, IL-25), thereby fueling a maladaptive Type 2 inflammatory loop. We further examine bacterial survival strategies, such as the formation of small colony variants (SCVs) and intracellular “Trojan Horse” reservoirs, which render conventional functional endoscopic sinus surgery (FESS) and antimicrobial monotherapies insufficient for complete eradication. Crucially, we discuss the current diagnostic disconnect where standard cultures fail to detect biofilm burdens. Finally, we propose a therapeutic paradigm shift from a purely bactericidal approach to one of ecological restoration. By integrating cutting-edge strategies, including matrix-degrading enzymes, bacteriophage cocktails, and Nasal Microbiota Transplantation (NMT), we construct a multi-dimensional framework aiming to restore sinonasal homeostasis. Together, these emerging strategies support a shift from pathogen suppression alone toward ecological and immunologic rebalancing of the sinonasal mucosa, offering a more durable conceptual framework for overcoming treatment recalcitrance.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.